Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor beta 1.

Hybridoma

Department of Bioanalytical Technology, Genentech, Inc., South San Francisco, California 94080, USA.

Published: June 1995

Transforming growth factor beta (TGF-beta) is a multifunctional peptide that controls proliferation, differentiation, and other functions in a variety of cell types. Transforming growth factor beta activities have been implicated in a variety of diseased states including arthritis, prostate cancer, and AIDS, and in the repair of tissue injury caused by trauma, burns, and surgery. We describe the development and characterization of novel murine monoclonal antibodies (MAbs) to the latency-associated peptide (LAP) of TGF-beta 1, and the subsequent development of an ELISA for the detection and quantitation of TGF-beta 1-LAP in buffer and serum matrices. Fusion of immune splenocytes with myeloma cells yielded 576 hybridomas, 110 of which were antibody secreting. Five were selected for extensive characterization. Clinically, the MAbs described here should be valuable for studying potentially abnormal production and/or function of the LAP, and its relationship to TGF-beta.

Download full-text PDF

Source
http://dx.doi.org/10.1089/hyb.1995.14.253DOI Listing

Publication Analysis

Top Keywords

transforming growth
12
growth factor
12
factor beta
12
development characterization
8
murine monoclonal
8
monoclonal antibodies
8
latency-associated peptide
8
characterization murine
4
antibodies latency-associated
4
peptide transforming
4

Similar Publications

Purpose: Although mechanical injury to the cornea (e.g. chronic eye rubbing) is a known risk factor for keratoconus progression, how it contributes to loss of corneal integrity is not known.

View Article and Find Full Text PDF

The impact of high heterogeneity of cancer-associated fibroblasts (CAFs) on triple-negative breast cancer (TNBC) immunotherapy response has not been fully elucidated, restricting progress in precision immuno-oncology. We integrated single-cell transcriptomic data from 18 TNBC patients and analyzed fibroblast subpopulations. Extracellular matrix CAFs (ecmCAFs) were identified as a fibroblast subpopulation with distinct ECM-associated characteristics.

View Article and Find Full Text PDF

Background: Recent years have seen persistently poor prognoses for glioma patients. Therefore, exploring the molecular subtyping of gliomas, identifying novel prognostic biomarkers, and understanding the characteristics of their immune microenvironments are crucial for improving treatment strategies and patient outcomes.

Methods: We integrated glioma datasets from multiple sources, employing Non-negative Matrix Factorization (NMF) to cluster samples and filter for differentially expressed metabolic genes.

View Article and Find Full Text PDF

Aims: This study aimed to develop a grounded theory that explains how nurses' experiences as patients or family members influence their provision of patient-centred care.

Design: A grounded theory approach.

Methods: Twenty clinical nurses in South Korea participated; nine had experiences as patients and 11 as family members during hospitalisation.

View Article and Find Full Text PDF

The Effects of 1,8-Cineole Treatment on Benign Prostatic Hyperplasia in Rats.

Curr Pharm Biotechnol

January 2025

Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.

Background: Benign prostatic hyperplasia is a non-malignant growth of the prostate gland; it's the most common prostatic growth in aging men. 1,8-cineole is a natural compound that is extracted from the essential oil of several aromatic plants including Eucalyptus spp. Recent studies have demonstrated the anti-inflammatory, antioxidant, and anticancer activities of 1,8-cineole.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!